 A strong financial performance is expected from AstraZeneca PLC LSE:AZN when the drug giant reports third-quarter figures early next month, according to City broker Shore Capital. Revenues for the three months ended September 30 are set to be in the region of US11bn, up 11, resulting in earnings per share of US1.52, ahead 41 on the same period last year. 